Renin-Angiotensin System Quantification in patients treated with specific medication against hypertension (Aliskiren or Candesartan)
Phase 1
- Conditions
- - Chronic kidney disease stages III-IV (defined by MDRD formula)- HypertensionTherapeutic area: Body processes [G] - Physiological processes [G07]
- Registration Number
- EUCTR2012-000250-55-AT
- Lead Sponsor
- Medizinische Universität Wien, Universitätsklinik für innere Medizin III
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Chronic kidney disease stages III-IV (defined by MDRD formula)
- Urinary albumin to creatinine ratio (UACR) >300mg/g, UACR >200mg/g if already receiving RAS blockade
- Hypertension
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 24
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 24
Exclusion Criteria
Age <18 years, diabetes mellitus type 2 (defined by WHO criteria), UACR >3500mg/g, severe hypertension, pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method